News Page
Published September 18, 2024
DexCom, Inc. develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. In the United States, about eleven percent of the population has diabetes, so DexCom seemed like a solid investment to many. That is, until July 2024, when DexCom announced disappointing financial results, and its stock price plummeted over 40 percent. Now shareholders claim that their losses aren’t just a disappointment, they’re the result of fraud.